Sagimet Biosciences Inc. (SGMT) Financial Statements
Free cash flow over the same period: -$41.7M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
SGMTSagimet Biosciences Inc.Follow SGMT — free
—
Price chart with a free account
- Market cap
- 595.5M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 12 Nov, in 19 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|
| Revenue | 2.0 | — | — | — | |
| Research & development | 19.8 | 38.4 | 39.1 | 35.0 | |
| Operating income | -30.7 | -54.5 | -56.9 | -52.6 | |
| Pre-tax income | -27.9 | -45.6 | -51.0 | -47.1 | |
| Income tax | — | — | 0.0 | — | |
| Net income | -27.9 | -45.6 | -51.0 | -47.1 | |
| Diluted EPS ($) | -2.66 | -1.45 | -1.58 | -0.89 | |
| Diluted shares (mn) | 10.5 | 31.4 | 32.3 | — |
USD millions · SEC XBRL
Sagimet Biosciences Inc. — questions
- What is Sagimet Biosciences Inc.'s net income?
- -$47.1M over the twelve months to 2026-06-30.
- What is Sagimet Biosciences Inc.'s free cash flow?
- -$41.7M over the twelve months to 2026-06-30.
- What are Sagimet Biosciences Inc.'s diluted earnings per share?
- $-0.89 over the twelve months to 2026-06-30.
Every figure on this page comes from Sagimet Biosciences Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.